Tonix Pharmaceuticals (TNXP) News Today $0.40 +0.02 (+5.29%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$0.38▼$0.4250-Day Range$0.38▼$0.5952-Week Range$0.37▼$9.81Volume2.27 million shsAverage Volume820,144 shsMarket Capitalization$9.49 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineZacks Small Cap Weighs in on Tonix Pharmaceuticals Holding Corp.'s FY2023 Earnings (NASDAQ:TNXP)americanbankingnews.com - December 9 at 1:40 AMTonix stock climbs as PWS therapy cleared for clinical studiesmsn.com - December 5 at 1:23 PMTonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - December 3 at 1:22 AMTonix Pharmaceuticals' CEO Reveals Next-Generation COVID Vaccine Technology chosen for key programproactiveinvestors.com - November 17 at 11:32 PMTonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorderfinance.yahoo.com - November 13 at 8:43 AMTonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlightsfinance.yahoo.com - November 9 at 7:00 PMWhy Tonix Pharmaceuticals (TNXP) Stock Is Falling Sharply Todaybenzinga.com - November 1 at 1:08 PMTonix to Stop Development of Depression Treatment After Study Resultsmarketwatch.com - October 31 at 8:14 PMTonix Shares Sink 29% on Discontinued Development on Depression Treatmentmarketwatch.com - October 31 at 8:14 PMTonix pulls plug on drug TNX-601 ER for depression, stock plunges 35%msn.com - October 31 at 8:14 PMmarketbeat.com - October 31 at 4:55 PMTonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:45 AMTonix Pharmaceuticals: New Hope for Long COVID Sufferersfinanznachrichten.de - October 27 at 6:44 PMTonix Pharmaceuticals expects topline results from migraine prevention study in Decemberproactiveinvestors.com - October 26 at 10:16 AMNew Hope for Long COVID Sufferersfinance.yahoo.com - October 25 at 1:09 PMTonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Modelsfinance.yahoo.com - October 18 at 7:41 AMTonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorderfinance.yahoo.com - October 16 at 7:49 AMTonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europefinance.yahoo.com - October 11 at 9:47 AMTonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conferencefinance.yahoo.com - October 9 at 8:02 AMTonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Painfinance.yahoo.com - October 4 at 9:32 AMWhy Tonix Pharmaceuticals (TNXP) Shares Are Getting Obliteratedbenzinga.com - September 30 at 9:58 AMTonix Pharmaceuticals Shares Tumble Premarket on Stock Salemarketwatch.com - September 29 at 8:23 AMTonix Pharma: Department Of Defense To Support Proposed Investigator Sponsored OASIS Trialmarkets.businessinsider.com - September 27 at 1:30 PMTNXP: Encouraging Topline Results for Long COVID Trial…finance.yahoo.com - September 26 at 2:38 PMTonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congressfinance.yahoo.com - September 18 at 9:22 AMTonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023finance.yahoo.com - September 14 at 8:52 AMTonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024finance.yahoo.com - September 6 at 10:00 AMTonix Pharma Shares Drop 11% After Covid Treatment Trial Misses Endpointmarketwatch.com - September 5 at 4:33 PMWhy Is Tonix Pharmaceuticals Stock Trading Lower Today?msn.com - September 5 at 4:33 PMTonix Pharmaceuticals: Topline Results for TNX-102 SL Miss Primary Endpointmarketwatch.com - September 5 at 8:12 AMTonix's long COVID drug fails to meet mid-stage trial goalreuters.com - September 5 at 8:12 AMTonix Pharma Reports Topline Results From Phase 2 PREVAIL Proof-of-Concept Study Of TNX-102 SLmarkets.businessinsider.com - September 5 at 8:12 AMTonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVIDfinance.yahoo.com - September 5 at 8:12 AMUPDATE 1-Tonix's long COVID drug fails to meet mid-stage trial goalfinance.yahoo.com - September 5 at 8:12 AMTonix Pharmaceuticals announces company is looking to...Tonix Pharmaceuticals announces company is looking to accelerate...proactiveinvestors.com - August 29 at 4:24 PMTonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participantsfinance.yahoo.com - August 21 at 4:34 PMTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpoxfinance.yahoo.com - August 21 at 9:23 AMTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlightsfinanznachrichten.de - August 11 at 6:38 AMTonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlightsfinance.yahoo.com - August 11 at 1:37 AMTonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorderfinance.yahoo.com - July 31 at 9:58 AMWhy Tonix Pharmaceuticals Stock Is Getting Obliteratedbenzinga.com - July 28 at 2:04 PMTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Proposed Public Offeringfinanznachrichten.de - July 28 at 9:03 AMTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offeringfinanznachrichten.de - July 28 at 9:03 AMTonix Pharmaceuticals stock sinks on pricing $7M public offeringseekingalpha.com - July 28 at 9:03 AMTonix Pharmaceuticals Shares Slide Premarket on Public Offeringmarketwatch.com - July 28 at 9:03 AMWhy Is Tonix Pharmaceuticals (TNXP) Stock Down 43% Today?msn.com - July 28 at 9:03 AMTonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023finance.yahoo.com - July 26 at 8:42 PMTonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Testfinance.yahoo.com - July 24 at 7:51 AMTonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorderfinance.yahoo.com - July 17 at 9:31 AMTonix Pharmaceuticals acquires pair of FDA-approved migraine products from Upsher-Smithproactiveinvestors.com - July 7 at 10:27 AM Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address TNXP Media Mentions By Week TNXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TNXP News Sentiment▼-0.470.52▲Average Medical News Sentiment TNXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TNXP Articles This Week▼51▲TNXP Articles Average Week Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Processa Pharmaceuticals News Bionomics News CNS Pharmaceuticals News Mustang Bio News GeoVax Labs News AcelRx Pharmaceuticals News ASLAN Pharmaceuticals News Virios Therapeutics News Frequency Therapeutics News ABVC BioPharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:TNXP) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.